160 related articles for article (PubMed ID: 11676178)
1. Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats.
Marumo H; Satoh K; Yamamoto A; Kaneta S; Ichihara K
Yakugaku Zasshi; 2001 Oct; 121(10):761-4. PubMed ID: 11676178
[TBL] [Abstract][Full Text] [Related]
2. 3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
Satoh M; Satoh A
J Pharm Pharm Sci; 2009 Feb; 11(2):118s-130s. PubMed ID: 19203474
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity.
Tesfamariam B; Frohlich BH; Gregg RE
J Cardiovasc Pharmacol; 1999 Jul; 34(1):95-101. PubMed ID: 10413074
[TBL] [Abstract][Full Text] [Related]
4. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
Rakotoniaina Z; Guerard P; Lirussi F; Goirand F; Rochette L; Dumas M; Bardou M
Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):195-206. PubMed ID: 17102939
[TBL] [Abstract][Full Text] [Related]
5. Hypotensive effect of atorvastatin is not related to changes in inflammation and oxidative stress.
Kuklińska AM; Mroczko B; Musiał WJ; Sawicki R; Kozieradzka A; Usowicz-Szaryńska M; Kamiński K; Knapp M; Szmitkowski M
Pharmacol Rep; 2010; 62(5):883-90. PubMed ID: 21098871
[TBL] [Abstract][Full Text] [Related]
6. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke.
Ferreira TS; Lanzetti M; Barroso MV; Rueff-Barroso CR; Benjamim CF; de Brito-Gitirana L; Porto LC; Valença SS
Inflammation; 2014 Oct; 37(5):1355-65. PubMed ID: 24609836
[TBL] [Abstract][Full Text] [Related]
8. Effect of statins on bone mineral density and bone histomorphometry in rodents.
Maritz FJ; Conradie MM; Hulley PA; Gopal R; Hough S
Arterioscler Thromb Vasc Biol; 2001 Oct; 21(10):1636-41. PubMed ID: 11597938
[TBL] [Abstract][Full Text] [Related]
9. Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats.
Hong SP; Chang KS; Choi DH; Choi JS
Arch Pharm Res; 2007 Jan; 30(1):90-5. PubMed ID: 17328247
[TBL] [Abstract][Full Text] [Related]
10. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study.
McMurtry MS; Bonnet S; Michelakis ED; Bonnet S; Haromy A; Archer SL
Am J Physiol Lung Cell Mol Physiol; 2007 Oct; 293(4):L933-40. PubMed ID: 17675370
[TBL] [Abstract][Full Text] [Related]
11. Pitavastatin: the newest HMG-CoA reductase inhibitor.
Watson KE
Rev Cardiovasc Med; 2010; 11(1):26-32. PubMed ID: 20495513
[TBL] [Abstract][Full Text] [Related]
12. HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.
Satoh K; Keimatsu N; Kanda M; Kasai T; Takaguri A; Sun F; Ichihara K
Biol Pharm Bull; 2005 Nov; 28(11):2092-5. PubMed ID: 16272695
[TBL] [Abstract][Full Text] [Related]
13. Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury.
Melo AC; Valença SS; Gitirana LB; Santos JC; Ribeiro ML; Machado MN; Magalhães CB; Zin WA; Porto LC
Int Immunopharmacol; 2013 Sep; 17(1):57-64. PubMed ID: 23747588
[TBL] [Abstract][Full Text] [Related]
14. LIFE and ARBITER.
Liebson PR
Prev Cardiol; 2003; 6(2):108-11. PubMed ID: 12732798
[No Abstract] [Full Text] [Related]
15. The effect of pravastatin and atorvastatin on coenzyme Q10.
Bleske BE; Willis RA; Anthony M; Casselberry N; Datwani M; Uhley VE; Secontine SG; Shea MJ
Am Heart J; 2001 Aug; 142(2):E2. PubMed ID: 11479481
[TBL] [Abstract][Full Text] [Related]
16. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs.
Satoh K; Ichihara K
J Cardiovasc Pharmacol; 2000 Feb; 35(2):256-62. PubMed ID: 10672858
[TBL] [Abstract][Full Text] [Related]
17. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
18. Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells.
Izidoro-Toledo TC; Guimaraes DA; Belo VA; Gerlach RF; Tanus-Santos JE
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jun; 383(6):547-54. PubMed ID: 21448567
[TBL] [Abstract][Full Text] [Related]
19. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
Conde K; Pineda G; Newton RS; Fernandez ML
Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
[TBL] [Abstract][Full Text] [Related]
20. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Cheung RC; Morrell JM; Kallend D; Watkins C; Schuster H
Int J Cardiol; 2005 Apr; 100(2):309-16. PubMed ID: 15823640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
